Danish Market Community
Our community narratives are driven by numbers and valuation.
Danish Investing Ideas
Global Weekly Picks
The $135 Billion Bet That Should Make Every Shareholder Nervous
DSV profits will jump by 7.4% thanks to growth trends
DSV A/S (CPH:DSV) — My Investment Thesis Hey everyone I'm Bejgal , and I want to share why I believe DSV is one of the most compelling logistics plays in Europe right now. My model points to a fair value of DKK 2,190 — a 22% discount to where it trades today.Read more
🚀 Why Ørsted is the Company of the Future?
Ørsted A/S (ORSTED) https://orsted.com/en/investors — is a Danish energy company that has transformed from a traditional oil and gas player (formerly DONG Energy) into the world's largest developer of offshore wind energy. As of February 2026, it is a key asset for the "green" portfolio, having completed a period of large-scale transformation and a profitability crisis.Read more
Why did Novo Nordisk flop?
Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems.Read more
Probably the best stock I've seen all year.
Cash Source Summary Their revenue has had a significant upwards trajectory growing 10%+ since FY21, with these trailing twelve months growing at ~17%. This growth is not there to a degree that is unsustainable, as 10%-30% growth can be achieved over time, and their proven track record is an even better sign of success.Read more
Novo Nordisk (NVO): Is the "Easy Growth" Story Over?
31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.Read more
Novo Nordisk - A Fundamental and Historical Valuation
Business Overview Total: 8.5/17 +2 ✅✅ Projected Operating Margin: 43.88% +1 ✅ Projected 5-Year Revenue CAGR: 11.93% +2 ✅✅ Last 5-Year ROIC: 54.60% +1 ✅ Estimated Cost of Capital: 7.54% (lower than ROIC) +1 ✅ Last 5-Year Shares Outstanding CAGR: -0.89% -1 ❌ Projected 5-Year EPS CAGR: 8.49% (given the easiness that the companies have in manipulating these numbers, below 10% represents a negative) +0 ⚠️ Projected 5-Year Dividend CAGR: 6.45% +1.5 ✅ Estimated Debt Rating: Aa3 +2 ✅✅ Morningstar Moat: Wide -1 ❌ Morningstar Uncertainty: High Novo Nordisk is the leader in obesity and diabetes treatments. Its wide moat is reflected on its stellar operating margin.Read more
Challenging Future for STG as Organic Sales Decline by 8.8%
Key Financial Results (Q1 2025) Reported net sales : DKK 2.0 billion ( +1.3% year-over-year ). Organic net sales growth : -8.8% , due to: Lower consumption of handmade cigars in the U.S. End of online distribution of ZYN in the U.S. Temporary supply issues caused by SAP implementation in European factories.Read more
EU#2 - From Humble Beginnings to Global Powerhouse
Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.Read more
